Compare CLFD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | RCKT |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.7M | 394.2M |
| IPO Year | 1995 | 2014 |
| Metric | CLFD | RCKT |
|---|---|---|
| Price | $29.27 | $3.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $43.50 | $29.73 |
| AVG Volume (30 Days) | 206.3K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | 26.37 |
| EPS | 0.14 | ★ 0.66 |
| Revenue | ★ $85,034,000.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $22.30 | $64.28 |
| P/E Ratio | $214.00 | ★ $5.48 |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.76 | $2.53 |
| 52 Week High | $52.73 | $5.45 |
| Indicator | CLFD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 51.47 |
| Support Level | $28.26 | $3.32 |
| Resistance Level | $30.99 | $3.65 |
| Average True Range (ATR) | 1.16 | 0.18 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 74.33 | 50.00 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.